These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies]. Hamon M Arch Mal Coeur Vaiss; 2006 Feb; 99 Spec no.3():5-9. PubMed ID: 16553237 [TBL] [Abstract][Full Text] [Related]
4. [Antithrombosis therapy in ischemic heart disease]. Cerveró Martí A; Echánove Errazquin I; Noguera Sanchis R Med Clin (Barc); 1988 Apr; 90(16):670-4. PubMed ID: 3294537 [No Abstract] [Full Text] [Related]
6. [Antithrombotic drugs in the acute coronary syndrome]. Jareño Chaumel A; Cercas Sánchez A Rev Clin Esp; 1996 Dec; 196(4 Monografico):26-38. PubMed ID: 9139329 [No Abstract] [Full Text] [Related]
7. Atherosclerosis and acute coronary syndromes. Gotlieb AI Cardiovasc Pathol; 2005; 14(4):181-4. PubMed ID: 16009315 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043 [TBL] [Abstract][Full Text] [Related]
9. [Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]. Leschke M; Schoebel FC; Strauer BE Internist (Berl); 1996 Jun; 37(6):597-606. PubMed ID: 8767992 [No Abstract] [Full Text] [Related]
10. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. Marmur JD J Invasive Cardiol; 2002 Apr; 14 Suppl B():8B-18B. PubMed ID: 11967386 [No Abstract] [Full Text] [Related]
11. [Use of new thrombin inhibitors in medical practice]. Blaya C; Prati C; Boneti C; Bonamigo DR; Krumenauer RC; Rosito GA Arq Bras Cardiol; 1998 Aug; 71(2):163-7. PubMed ID: 9816691 [No Abstract] [Full Text] [Related]
12. The role of magnesium as antithrombotic therapy. Shechter M Wien Med Wochenschr; 2000; 150(15-16):343-7. PubMed ID: 11105330 [TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of thrombosis and fibrinolysis during acute myocardial infarction. Jaffe AS; Eisenberg PR; Wilner GD Prog Hematol; 1987; 15():71-89. PubMed ID: 3332392 [No Abstract] [Full Text] [Related]
14. Direct thrombin inhibitors (part 1 of 2). Arora UK; Dhir M J Invasive Cardiol; 2005 Jan; 17(1):34-8. PubMed ID: 15640538 [No Abstract] [Full Text] [Related]
15. Viewpoint: megatrials and the development of antithrombotics. Polak M Circulation; 2006 Jun; 113(25):f97. PubMed ID: 16801471 [No Abstract] [Full Text] [Related]
16. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935 [TBL] [Abstract][Full Text] [Related]
17. New strategies in the management of acute coronary syndromes. Fullwood J; Butler G; Smith T; Cox M; Bride W; Mostaghimi Z; Cook PS; Granger BB Nurs Clin North Am; 2000 Dec; 35(4):877-95. PubMed ID: 11072276 [TBL] [Abstract][Full Text] [Related]